{
    "clinical_study": {
        "@rank": "36675", 
        "arm_group": [
            {
                "arm_group_label": "Extended Treatment time", 
                "arm_group_type": "Experimental", 
                "description": "Extended treatment time of 6 hours"
            }, 
            {
                "arm_group_label": "standard treatment time", 
                "arm_group_type": "Active Comparator", 
                "description": "Standard Treatment time of 4 hours"
            }
        ], 
        "brief_summary": {
            "textblock": "Design: Prospective randomised cross-over study. Fifty-two eligible patients will be\n      randomised to a treatment time of either 6 hours or 4 hours for a period of 24 weeks and\n      following a washout period of 4 weeks, switch to the alternative treatment time for an\n      additional 24 weeks.\n\n      Aims: To examine the feasibility and effect of extended dialysis treatment time, 6 hours\n      thrice weekly, versus the standard, 4 hours thrice weekly, comparing the differences from\n      baseline in outcome measures over a total 12-month period.\n\n      Primary outcome measure\n\n      1]Serum albumin\n\n      Secondary outcome measures Nutritional status\n\n        1. Malnutrition-inflammation score\n\n        2. Dietary intake\n\n        3. Hand-Grip strength\n\n        4. Energy expenditure\n\n      Quality of life\n\n        1. Patient reported quality of life and\n\n        2. time to recovery from dialysis\n\n      Serum biomarkers\n\n        1. BNP\n\n        2. Troponin\n\n        3. MCP-1\n\n      Others 24- hour Ambulatory blood pressure 24-hour accelerometer\n\n      Population: Local haemodialysis population of 1200 patients Eligibility: Minimum 90days on\n      haemodialysis treatment Duration:  Fifty-six weeks"
        }, 
        "brief_title": "Effects of Extended Haemodialysis Treatment Duration in Patients With End-stage Renal Disease", 
        "completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "End Stage Renal Disease", 
        "condition_browse": {
            "mesh_term": [
                "Kidney Diseases", 
                "Kidney Failure, Chronic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Dialysis dependant for over 90 days\n\n        Exclusion Criteria:\n\n          1. Haemodialysis for less than 90 days\n\n          2. Patients with anticipated life expectancy less than 6 months secondary to significant\n             morbidity e.g. metastatic malignancy, advanced human immunodeficiency virus\n\n          3. Patients with acute liver disease; History of underlying haematological condition;\n\n          4. Elective planned change of renal replacement modality within the 12 months."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "52", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 1, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01721421", 
            "org_study_id": "11-LL-0505"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Extended Treatment time", 
                    "standard treatment time"
                ], 
                "description": "patients receive extended dialysis treatment time time of 6 hours", 
                "intervention_name": "extended treatment time", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": [
                    "Extended Treatment time", 
                    "standard treatment time"
                ], 
                "intervention_name": "Standard treatment time", 
                "intervention_type": "Other"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "haemodialysis", 
            "Crossover", 
            "Treatment time", 
            "nutritional status"
        ], 
        "lastchanged_date": "November 2, 2012", 
        "location": {
            "contact": {
                "email": "s.singh11@imperial.ac.uk", 
                "last_name": "Seema Singh, MSc", 
                "phone": "+44 2083835249"
            }, 
            "facility": {
                "address": {
                    "city": "London", 
                    "country": "United Kingdom", 
                    "zip": "W12 0HS"
                }, 
                "name": "Imperial College Healthcare NHS Trust"
            }, 
            "investigator": [
                {
                    "last_name": "Seema Singh, MSc", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Charles Pusey", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Peter Choi, PhD MD", 
                    "role": "Principal Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "number_of_arms": "2", 
        "official_title": "Feasibility and Physiological and Nutritional Effects of Extended Treatment Duration in Patients With End-stage Renal Disease on Haemodialysis", 
        "overall_contact": {
            "email": "s.singh11@imperial.ac.uk", 
            "last_name": "Seema Singh", 
            "phone": "+44 208 3835249"
        }, 
        "overall_official": {
            "affiliation": "Imperial College London", 
            "last_name": "Peter Choi, MBcHB PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United Kingdom: National Institute for Health Research", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "March 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Serum albumin", 
            "safety_issue": "No", 
            "time_frame": "baseline to 24 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01721421"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Imperial College London", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Imperial College London", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2011", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Health Services Research", 
        "study_type": "Interventional", 
        "verification_date": "November 2012"
    }
}